Microdose Announces Mindstate Design Labs as Wonderland 2022 Platinum Sponsor

The article Microdose Announces Mindstate Design Labs as Wonderland 2022 Platinum Sponsor was originally published on Microdose.

The leader in the business of psychedelics, Microdose is taking the next step in top-notch industry events with Wonderland 2022. Pulling off such a massive undertaking wouldn’t be possible without the support of our sponsors, they are crucial to both the Wonderland event and the future of the psychedelic medicine industry.

So it’s an honor for Microdose to announce Mindstate Design Labs as a Platinum Sponsor for Wonderland: Miami 2022.

Dillan DiNardo, CEO of  Mindstate Design Labs will be at Wonderland for the following events:

• Ending the War on Drugs panel on November 3rd, 10:00 am EST
• Intentional Design of Novel Modified Conscious States panel on November 5th 3:00 pm EST

About Mindstate Design Labs:

Launched out of Y Combinator in 2021, Mindstate Design Labs is a preclinical-stage psychedelic drug development company designing states of consciousness for mental health therapeutics. Recognizing the acute subjective experience of an altered state as central to treatment outcomes, the company is mapping the biological basis of the varieties of psychedelic experience.

Mindstate Design Labs’ lead drug program is designed to produce the entactogenic state while minimizing the negative side effects and allowing for a greater number of treatment sessions. Phase I clinical trials are slated for 2023. The company’s lead program is followed by a pipeline of additional drug candidates designed to selectively produce various psychedelic effects for the treatment of different mental health disorders.

Mindstate’s target discovery and phenotypic screening platform Osmanthus is powered by human experience, combining natural history, natural language processing, and biochemical data in a predictive model that enables the precision design of modified conscious states.

Osmanthus combines natural history, biochemical data, and artificial intelligence to identify and validate patterns linking biochemical data to qualitative human reports of drug effects. Databases from human reports of the effects of various psychedelics over the last 50 years have provided crucial data for the Osmanthus platform’s natural history and computational AI techniques. Mindstate now uses the resulting pattern identification to prioritize its pipeline of primer/probe combinations for advancement to clinical trials.

We are continuing to build out what is already the world’s most robust database of phenomenological and biochemical data on psychedelic compounds: > 7,000 experience reports synthesized with assays of dozens of compounds against > 50 receptors, transporters, and ion channels.

Read More